Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: Utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost

Journal of Virology

Volumn 74, Issue 24, 2000, Pages 11935-11949

  Gorelick, R J ^a   Benveniste, R E ^a   Lifson, J D ^a   Yovandich, J L ^a   Morton, W R ^a   Kuller, L ^a   Flynn, B M ^a   Fisher, B A ^a   Rossio, J L ^a   Piatak M , Jr ^a   Bess J W , Jr ^a   Henderson, L E ^a   Arthur, L O ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EPITOPE; NEUTRALIZING ANTIBODY; NUCLEOCAPSID PROTEIN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DELETION MUTANT; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MACACA; MALE; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VIRION; VIRUS CAPSID; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; DNA, VIRAL; MACACA NEMESTRINA; MUTATION; NUCLEOCAPSID PROTEINS; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, DNA;

EID: 0034466819     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.24.11935-11949.2000     Document Type: Article

References (66)

1. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells
2. Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: A candidate SIV vaccine
3. Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus
4. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques
5. Vaccine effect using a live attenuated nef-deficient simian immunodeficiency virus of African green monkeys in the absence of detectable vaccine virus replication in vivo
6. Isolation of a lentivirus from a macaque with lymphoma: Comparison with HTLV-III/LAV and other lentiviruses
7. Characterization of clones of HIV-1 infected HuT 78 cells defective in gag gene processing and of SIV clones producing large amounts of envelope glycoprotein
8. Long-term protection of macaques against high-dose type D retrovirus challenge after immunization with recombinant vaccinia virus expressing envelope glycoproteins
9. Inoculation of baboons and macaques with simian immunodeficiency virus/Mne, a primate lentivirus closely related to human immunodeficiency virus type 2
10. Molecular characterization and comparison of simian immunodeficiency virus isolates from macaques, mangabeys, and African green monkeys
11. Infectivity of titered doses of simian immunodeficiency virus clone E11S inoculated intravenously into rhesus macaques (Macaca mulatta)
12. Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: Consequences of challenge
13. Phenotypic variation in the response to the human immunodeficiency virus among derivatives of the CEM T and WIL-2 B cell lines
14. T-cell proliferation to subinfectious SIV correlates with lack of infection after challenge of macaques
15. Facilitated DNA inoculation induces anti-HIV-1 immunity in vivo
16. Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine
17. In vivo resistance to simian immunodeficiency virus superinfection depends on attenuated virus dose
18. Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa
19. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
20. Identification of highly attenuated mutants of simian immunodeficiency virus
21. Vaccine protection against simian immunodeficiency virus infection
22. Ultrastructural studies of surface features of human normal and tumor cells in tissue culture by scanning and transmission electron microscopy
23. Nucleocapsid protein zinc-finger mutants of simian immunodeficiency virus strain Mne produce virions that are replication defective in vitro and in vivo
24. Genetic analysis of the zinc finger in the Moloney murine leukemia virus nucleocapsid domain: Replacement of zinc-coordinating residues with other zinc-coordinating residues yields noninfectious particles containing genomic RNA
25. The two zinc fingers in the human immunodeficiency virus type 1 nucleocapsid protein are not functionally equivalent
26. Characterization of the block in replication of nucleocapsid protein zinc finger mutants from Moloney murine leukemia virus
27. Strict conservation of the retroviral nucleocapsid protein zinc finger is strongly influenced by its role in viral infection processes: Characterization of HIV-1 particles containing mutant nucleocapsid zinc-coordinating sequences
28. Point mutants of Moloney murine leukemia virus that fail to package viral RNA: Evidence for specific RNA recognition by a "zinc finger-like" protein sequence
29. Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA
30. Env-independent protection induced by live, attenuated simian immunodeficiency virus vaccines
31. Protection from pathogenic SIV challenge using multigenic DNA vaccines
32. Vaccine protection and reduced virus load from heterologous macaque-propagated SIV challenge
33. Sequence diversity of SIV(Mne) Nef in vivo and in vitro
34. HIV vaccines - Where are we going?
35. Molecular characterization of gag proteins from simian immunodeficiency virus (SIVMne)
36. DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies
37. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160
38. Protection of monkeys vaccinated with vpr- and/or nef-defective simian immunodeficiency virus strain mac/human immunodeficiency virus type 1 chimeric viruses: A potential candidate live-attenuated human AIDS vaccine
39. Protective immunity induced by live attenuated simian immunodeficiency virus
40. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: Inverse relationship of degree of protection with level of attenuation
41. Intrarectal inoculation of macaques by the simian immunodeficiency virus, SIVmne E11S: CD4+ depletion and AIDS
42. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV
43. Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis, treatment and prevention
44. The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection
45. Containment of simian immunodeficiency virus infection: Cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment
46. Protection from pathogenic SIVmac challenge following short-term infection with a nef-deficient attenuated virus
47. Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines
48. Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in macaques
49. Long-term protection against SIV-induced disease in macaques vaccinated with a live attenuated HIV-2 vaccine
50. Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope
51. DNA vaccines for immunodeficiency viruses
52. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
53. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins
54. "Attenuated" simian immunodeficiency virus in macaque neonates
55. Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus
56. Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus
57. Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection
58. Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction
59. Live attenuated simian immunodeficiency virus prevents super-infection by cloned SIVmac251 in cynomolgus monkeys
60. Infectivity and pathogenesis of titered dosages of simian immunodeficiency virus experimentally inoculated into longtailed macaques (Macaca fascicularis)
61. Heterologous protection against influenza by injection of DNA encoding a viral protein
62. Gene inoculation generates immune responses against human immunodeficiency virus type 1
63. Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions
64. Plasma viremia in macaques infected with simian immunodeficiency virus: Plasma viral load early in infection predicts survival
65. Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys
66. NC results in subtle differences in Gag processing and virion maturation associated with degradative loss of mutant NC